



<p>Recipient Information</p> <p>1. Recipient Name ECOHEALTH ALLIANCE INC. 520 8TH AVE RM 1200 NEW YORK, NY 10018</p> <p>2. Congressional District of Recipient 12</p> <p>3. Payment System Identifier (ID) 1311726494A1</p> <p>4. Employer Identification Number (EIN) 311726494</p> <p>5. Data Universal Numbering System (DUNS) 077090066</p> <p>6. Recipient's Unique Entity Identifier TKS7NBB4JDN6</p> <p>7. Project Director or Principal Investigator Peter Daszak, PHD Executive Director daszak@ecohealthalliance.org 212-380-4460</p> <p>8. Authorized Official Aleksei Chmura chmura@ecohealthalliance.org 212-380-4473</p>	<p>Federal Award Information</p> <p>11. Award Number 5R01AI110964-07</p> <p>12. Unique Federal Award Identification Number (FAIN) R01AI110964</p> <p>13. Statutory Authority 42 USC 241 42 CFR 52</p> <p>14. Federal Award Project Title Understanding the Risk of Bat Coronavirus Emergence</p> <p>15. Assistance Listing Number 93.855</p> <p>16. Assistance Listing Program Title Allergy and Infectious Diseases Research</p> <p>17. Award Action Type Non-Competing Continuation</p> <p>18. Is the Award R&D? Yes</p>																								
<p>Federal Agency Information</p> <p>9. Awarding Agency Contact Information Shaun W Gratton Grants Management Specialist NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES Shaun.Gratton@nih.gov 240-627-3594</p> <p>10. Program Official Contact Information Erik J. Stemmy Program Officer NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES erik.stemmy@nih.gov 240-627-3380</p>	<p>Summary Federal Award Financial Information</p> <table border="1"> <tr> <td colspan="2">19. Budget Period Start Date 05/01/2023 – End Date 04/30/2024</td> </tr> <tr> <td>20. Total Amount of Federal Funds Obligated by this Action</td> <td style="text-align: right;">\$576,290</td> </tr> <tr> <td> 20 a. Direct Cost Amount</td> <td style="text-align: right;">\$482,506</td> </tr> <tr> <td> 20 b. Indirect Cost Amount</td> <td style="text-align: right;">\$93,784</td> </tr> <tr> <td>21. Authorized Carryover</td> <td></td> </tr> <tr> <td>22. Offset</td> <td></td> </tr> <tr> <td>23. Total Amount of Federal Funds Obligated this budget period</td> <td style="text-align: right;">\$576,290</td> </tr> <tr> <td>24. Total Approved Cost Sharing or Matching, where applicable</td> <td style="text-align: right;">\$0</td> </tr> <tr> <td>25. Total Federal and Non-Federal Approved this Budget Period</td> <td style="text-align: right;">\$576,290</td> </tr> <tr> <td colspan="2">-----</td> </tr> <tr> <td colspan="2">26. Project Period Start Date 06/01/2014 – End Date 04/30/2027</td> </tr> <tr> <td>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</td> <td style="text-align: right;">\$1,238,270</td> </tr> </table> <p>28. Authorized Treatment of Program Income Additional Costs</p> <p>29. Grants Management Officer - Signature Emily Linde</p>	19. Budget Period Start Date 05/01/2023 – End Date 04/30/2024		20. Total Amount of Federal Funds Obligated by this Action	\$576,290	20 a. Direct Cost Amount	\$482,506	20 b. Indirect Cost Amount	\$93,784	21. Authorized Carryover		22. Offset		23. Total Amount of Federal Funds Obligated this budget period	\$576,290	24. Total Approved Cost Sharing or Matching, where applicable	\$0	25. Total Federal and Non-Federal Approved this Budget Period	\$576,290	-----		26. Project Period Start Date 06/01/2014 – End Date 04/30/2027		27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$1,238,270
19. Budget Period Start Date 05/01/2023 – End Date 04/30/2024																									
20. Total Amount of Federal Funds Obligated by this Action	\$576,290																								
20 a. Direct Cost Amount	\$482,506																								
20 b. Indirect Cost Amount	\$93,784																								
21. Authorized Carryover																									
22. Offset																									
23. Total Amount of Federal Funds Obligated this budget period	\$576,290																								
24. Total Approved Cost Sharing or Matching, where applicable	\$0																								
25. Total Federal and Non-Federal Approved this Budget Period	\$576,290																								

26. Project Period Start Date 06/01/2014 – End Date 04/30/2027																									
27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$1,238,270																								
<p>30. Remarks Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.</p>																									



RESEARCH
Department of Health and Human Services
National Institutes of Health



NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

SECTION I – AWARD DATA – 5R01AI110964-07

Principal Investigator(s):

Peter Daszak, PHD

Award e-mailed to: chmura@ecohealthalliance.org

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$576,290 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to EcoHealth Alliance in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI110964. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Emily Linde
Grants Management Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows

Cumulative Award Calculations for this Budget Period (U.S. Dollars)

Salaries and Wages	\$151,359
Fringe Benefits	\$47,686
Personnel Costs (Subtotal)	\$199,045
Consultant Services	\$38,337
Travel	\$30,417
Other	\$19,276
Subawards/Consortium/Contractual Costs	\$189,431
Publication Costs	\$6,000
Federal Direct Costs	\$482,506
Federal F&A Costs	\$93,784
Approved Budget	\$576,290
Total Amount of Federal Funds Authorized (Federal Share)	\$576,290
TOTAL FEDERAL AWARD AMOUNT	\$576,290
AMOUNT OF THIS ACTION (FEDERAL SHARE)	\$576,290

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
7	\$576,290	\$576,290
8	\$568,370	\$568,370
9	\$568,370	\$568,370
10	\$568,370	\$568,370

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

Payment System Identifier: 1311726494A1
Document Number: RAI110964B
PMS Account Type: P (Subaccount)
Fiscal Year: 2023

IC	CAN	2023	2024	2025	2026
AI	8472364	\$576,290	\$568,370	\$568,370	\$568,370

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: M51C B / OC: 41025 / Released: Linde, Emily 04/26/2023
Award Processed: 04/27/2023 12:01:45 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 5R01AI110964-07

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – STANDARD TERMS AND CONDITIONS – 5R01AI110964-07

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This grant is excluded from Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01AI110964. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

Recipients must administer the project in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age, and comply with applicable conscience protections. The recipient will comply with applicable laws that prohibit discrimination on the basis of sex, which includes discrimination on the basis of gender identity, sexual orientation, and pregnancy. Compliance with these laws requires taking reasonable steps to provide meaningful access to persons with limited English proficiency and providing programs that are accessible to and usable by

persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See <https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html> and <https://www.hhs.gov/>.

- Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals, see <https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html> and <https://www.lep.gov>.
- For information on an institution's specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and to provide effective communication, see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>.
- HHS funded health and education programs must be administered in an environment free of sexual harassment; see <https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html>. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see <https://grants.nih.gov/grants/policy/harassment.htm>.
- For guidance on administering programs in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws, see <https://www.hhs.gov/conscience/conscience-protections/index.html> and <https://www.hhs.gov/conscience/religious-freedom/index.html>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:

Additional Costs

SECTION IV – AI SPECIFIC AWARD CONDITIONS – 5R01AI110964-07

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

THIS AWARD CONTAINS GRANT SPECIFIC RESTRICTIONS. THESE RESTRICTIONS MAY ONLY BE LIFTED BY A REVISED NOTICE OF AWARD.

Restriction:

The recipient will, prior to entering into any subaward agreements, initial or subsequent, submit the subaward agreements to NIAID for prior approval, in accordance with the policy requirements outlined in NIHGPS [Section 8.1.3 Requests for Prior Approval](#). Written agreements must be submitted at the following times:

- The recipient must immediately renegotiate all activities performed under subawards made from this award agreement. NIAID must approve the renegotiated subaward

agreement prior to permitting any work by that subrecipient organization. NIAID will only approve subaward agreements meeting the minimum requirements set forth in [NIHGPS Section 15.2, Administrative and Other Requirements](#).

- **Once** the written subaward agreement is approved, the recipient must request prior approval prior to making any further revisions to the agreement. Prior approval requests may be submitted directly to the NIAID Grants Management Official named in the Notice of Award not later than 30 days before the proposed effective date of the revision.
- For future subawards requested during the period of performance, and in accordance with NIHGPS [Section 8.1.3 Requests for Prior Approval](#), the recipient must submit the draft terms of the written agreement not later than 30 days before the proposed start of the subaward. Note: the subaward may not start until NIAID's GMO approves the terms of the agreement, no exception.
- For future subawards identified in a competing grant application, NIH will require the written agreement as a part of Just-in-Time (See [NIHGPS Section 2.5.1 Just-in-Time Procedures](#)). NIAID must approve the subaward agreement prior to its finalization.

Specifically, NIAID will approve all written subaward agreements that include, at a minimum, the specific requirements set forth in NIHGPS [Section 15.2 Administrative and Other Requirements](#). Any subaward agreements that do not meet the minimum requirements, will not be approved, without exception.

Restriction:

All funds for this award are restricted and require NIAID approval of cost reimbursement. The recipient must submit requests for reimbursement to NIAID in accordance with the letter from Michelle G. Bulls, dated April 26, 2023.

To ensure that grant payments are received, reviewed, and processed in a timely manner the recipient must adhere to the following conditions, as outlined below:

The recipient is required to provide NIAID with a detailed listing of actual expenses incurred, along with supporting documentation, to justify all monthly drawdown requests for funds from PMS using the format provided in the letter. The list of actual monthly detailed expenditures must be submitted via the provided unlocked spreadsheet, with expenses reported by budget category. Supporting documentation for each expense, including all products and services and subawards, must be included with the request in order to justify all requested costs. Acceptable documentation includes signed and approved timesheets with description of work performed for all personnel expenses; invoices for supplies, equipment, services or subawards with a description of the need and how it relates to the aims of the grant; a complete accounting of travel expenses (e.g., hotel, air, per diem) and an explanation of the reason for travel and how it relates to the aims of the grant, etc. If you have other categories of expenses, contact the NIAID grants management specialist to discuss documentation requirements. NIAID must approve all drawdown requests before funds can be accessed in PMS. Please submit drawdown requests and supporting documentation to:

Shaun Gratton
Lead Grants Management Specialist
National Institute of Allergy and Infectious Diseases

National Institute of Health, DHHS
5601 Fishers Lane, Room 4G48, MSC 9824
Bethesda, MD 20892-9824
Phone: (240) 627-3594
Fax: (301) 493-0597
Email: shaun.gratton@nih.gov

All requests must be received by NIAID at least 20 business days prior to anticipated drawdown by the recipient to provide sufficient time for review and approval by NIAID and transmission to PMS to ensure timely drawdowns.

Restriction:

The recipient must develop or improve written policies and procedures to comply with NIH requirements for:

- a. Charging costs to NIAID awards in accordance with NIHGPS [Section 7.2 The Cost Principles](#). Policies should contain, at a minimum, information on roles and responsibilities; definitions; disclosure, review, and approval requirements and processes; timeliness of reporting, and consequences for noncompliance.
- b. Entering into and monitoring subawards agreements under NIHGPS [Section 15 Consortium Agreements](#). Policies and procedures must contain, at a minimum, information on roles and responsibilities; definitions; internal review and approval requirements and processes; how to negotiate subaward agreements; how to monitor subaward agreements, and consequences for noncompliance.

These policies and procedures shall be provided to NIAID for review no later than September 15, 2023. The new or revised policies and procedures may not be implemented until approved by NIAID in writing.

Restriction:

The recipient must obtain an independent third-party financial audit. This audit must be a comprehensive review to determine if:

- Accounting practices are aligned with [2 C.F.R. § 200.302](#), Financial Management
- EHA is financially capable of managing NIH grant funds in accordance with [2 C.F.R. § 200.302](#) Financial Management and maintains sufficient internal controls as required by [2 C.F.R. § 200.303](#), Internal Controls.
- Financial records are properly maintained as required by [2 C.F.R. § 200.334](#), Retention requirements for records.
- Financial reports are submitted to NIH timely and accurately.
- The recipient has complied with applicable laws, regulations, and terms and conditions of award.

The time period of the review must cover the period October 1, 2020, through April 26, 2023.

The independent third-party auditor must be an organization that has not conducted the annual audit for the recipient organization in the past five years. ERHA must submit potential firms to NIH for review by May 26, 2023. NIH will determine and communicate to EHA whether the selection is acceptable. The costs for the independent third-party audit may not be charged to NIH grants.

The report from this review must be provided to NIAID for review no later than September 15, 2023, unless NIAID agrees in writing to accept the report at a later date.

Restriction: This award is being issued **without** the foreign component at King George’s Medical University, INDIA. No work or collaboration may be conducted under this award with King George’s Medical University, INDIA.

This award reflects the termination of subaward from EcoHealth Alliance (EHA) to the Wuhan Institute of Virology (WIV), and subsequent renegotiation of the award as reflected in the letter from EHA dated 11/17/2022.

Vertebrate Animals: In accordance with information provided in the [award renegotiation documentation](#) vertebrate animals will no longer be utilized in this project. If plans change, a valid IACUC approval for the use of animals must be submitted to the NIAID Grants Management Specialist for prior approval prior to utilization of animals on this project.

Human Subjects: In accordance with information provided in award renegotiation documents, this project no longer involves non-exempt human subjects research. If plans change, a valid IRB approval date for the use of human subjects must be submitted to the NIAID Grants Management Specialist for prior approval prior to conducting non-exempt human subjects research. For more information on what is and is not considered Human Subjects Research please visit,

https://grants.nih.gov/sites/default/files/HS_infographic_NIH_rev%20rp4%20508c%204-1-19.pdf

The recipient must provide NIAID with copies of FFATA Subaward Reporting System (FSRS) reporting of all (existing and newly established) subaward agreements within 30 days of submitting to FSRS.

The recipient must provide NIH with copies of updated subaward agreements within 30 days of execution of any initial and subsequent subaward agreement(s). The subaward agreements must demonstrate compliance with the NIH Grants Policy Statement (NIH GPS) 15.2.1 Written Agreement. The subaward agreements must state the correct F&A rate which, for foreign subrecipients is 8% (see NIH GPS 16.6) and include descriptions of the biosafety monitoring plans for each project, where appropriate.

Failure to comply with this special condition can result in withholding of support, audit disallowances, suspension and/or termination of this award, and/or other appropriate enforcement actions. This award is subject to the Transparency Act subaward reporting requirement of 2 CFR Part 170, which must be reported through the Federal Funding Accountability and Transparency Subaward Reporting System (FSRS).

The recipient is required to submit semi-annual progress reports, Research Performance Progress Report (RPPR), and Cumulative Federal Financial Reports (FFR) to NIAID via the Request for Additional Materials (RAM) module within Electronic Research Administration (eRA). The semi-annual reports for this budget period is due on **November 1, 2023**. NIAID will initiate a RAM request within eRA at least 15 days prior to the due date of the semi-annual progress report, RPPR and FFR. Upon receipt of the RAM request, the recipient is required to upload the requested documents in Commons within RAM no later than the due date listed above.

The recipient must conduct or arrange for the conduct of onsite subrecipient facility inspections every 6 months to ensure that subaward activities are being properly executed. The recipient must provide certification in the Research Performance Progress Report that it is in compliance with this term and condition of award.

This award does not have the no-cost extension authority of the NIH Standard Terms and Conditions of Award. NIAID prior approval is required to extend the project period end date for this award

This Notice of Award (NoA) includes funds for Duke-NUS – SINGAPORE in the amount of \$189,431.

The recipient must notify the US Embassy in Burma/Myanmar prior to any travel to that country.

The Research Performance Progress Report (RPPR), Section G.9 (Foreign component), includes reporting requirements for all research performed outside of the United States. Research conducted at the following site(s) must be reported in your RPPR:

INTERNATIONAL CTR/DIARRHOEAL DIS RES (ICDDR'B) – BANGLADESH
National Health Laboratory – BURMA
INSTITUT PASTEUR DU CAMBODGE - CAMBODIA
BOGOR AGRICULTURAL UNIVERSITY – INDONESIA
Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit – LAOS
Conservation Medicine, Ltd – MALAYSIA
Oxford University Clinical Research Unit – VIETNAM
Duke-NUS Medical School – SINGAPORE
Chulalongkorn University – THAILAND

Dissemination of study data will be in accord with the Recipient's accepted genomic data sharing plan as stated in the page(s) **203** of the application. Failure to adhere to the sharing plan as mutually agreed upon by the Recipient and the NIAID may result in Enforcement Actions as described in the NIH Grants Policy Statement.

Funds provided on this award may not be used to support research subject to the Department of Health and Human Services Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens (DHHS P3CO Framework).

Recipients conducting research involving Select Agents (see 42 CFR 73 for the relevant human Select Agents and Toxins; and 7 CFR 331 and 9 CFR 121 for the relevant animal and plant Select Agents and Toxins at <https://www.selectagents.gov/regulations/>) must complete registration with CDC (or APHIS, depending on the agent) before using NIH funds for any work directly involving the Select Agent at the US institution. No funds can be used for research involving Select Agents if the final registration certificate is denied. Prior to conducting a restricted experiment with a Select Agent or Toxin, recipients must notify the NIAID and must request and receive approval from CDC or APHIS.

Before using NIH funds for any work directly involving the Select Agents at the foreign institution, the US recipient must provide information from the foreign institution satisfactory to the NIAID that processes and requirements comparable to those described in 42 CFR 73 for US institutions are in place and will be administered on behalf of all Select Agent work sponsored by NIH funds.

The recipient must work with the foreign institution to ensure:

- Institution understands the NIAID Select Agent Policy and requirements,
- Institution is willing and able to allow the NIAID representatives to enter and review the laboratories or facilities where Select Agent research is (or will be) conducted and the area(s) where NIAID funded select agents and toxins are stored,
- Institution is willing and able to allow site reviews every three years after the initial review
- And that, for the visit, institution is willing to address the following key elements appropriate for their institution: safety, security, incident response plan, training, procedures for personnel security risk assessment ensuring that only approved/appropriate individuals have access to the Select Agents, and any applicable laws, regulations and policies equivalent to 42 CFR 73.

Once approval for Select Agent work is provided, the recipient is solely responsible for ensuring the work sponsored by NIH funds is administered as approved, in a manner consistent with 42 CFR 73. If this work will not, in fact, involve Select Agents subject to the provisions of the US Select Agents regulations (e.g. excluded strains), and the US recipient provides documentation satisfactory to the NIAID that the work does not now nor will it in the future (i.e. throughout the life of the award) involve Select Agents at the foreign institution, no further action will be necessary.

Prior to conducting a restricted experiment with a Select Agent or Toxin, recipients must notify NIAID and request and receive approval. Changes in the use of a Select Agent will be considered a change in scope and require NIH awarding office prior approval. The approval is necessary for new select agent experiments as well as changes in on-going experiments that would require change in the biosafety plan and/or biosafety containment level. An approval to conduct a restricted experiment granted to an individual cannot be assumed an approval to other individuals who conduct the same restricted experiment as defined in the Select Agents Regulation 42 CFR Part 73, Section 13.b (<https://www.selectagents.gov/regulations/>) and the U.S. Federal Select Agent Program (<https://www.selectagents.gov/compliance/guidance/restricted/>). Be advised that the recipient is responsible for having its subrecipients comply with the requirements pertaining to the use of Select Agents and/or Highly Pathogenic Agents.

Highly Pathogenic Agents:

NIAID defines a Highly Pathogenic Agent as an infectious Agent or Toxin that may warrant a biocontainment safety level of BSL3 or higher according to the current edition of the CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL) (<https://www.cdc.gov/labs/BMBL.html>). Research funded under this grant must adhere to the BMBL, including using the BMBL-recommended biocontainment level at a minimum. If the Institutional Biosafety Committee (IBC) (or equivalent body) or designated institutional biosafety official recommends a higher biocontainment level, the higher recommended containment level must be used.

When submitting future Progress Reports indicate at the beginning of the report:

If no research with a Select Agent (see 42 CFR 73 for the relevant human Select Agents and Toxins; and 7 CFR 331 and 9 CFR 121 for the relevant animal and plant Select Agents and Toxins at <https://www.selectagents.gov/regulations/> and <https://www.selectagents.gov/sat/list.htm>) and/or has been performed or is planned to be performed under this grant.

If the IBC or equivalent body or official has determined, for example, by conducting a risk assessment, that the work being planned or performed under this grant may be conducted at a biocontainment safety level that is lower than BSL3.

If the work involves Select Agents and/or Highly Pathogenic Agents, also address the following points:

Any NIAID pre-approved changes in the use of the Select Agents and/or Highly Pathogenic Agents including its restricted experiments that have resulted in a change in the required biocontainment level, and any resultant change in location, if applicable, as determined by the IBC or equivalent body or official.

If work with a new or additional Select Agents and/or Highly Pathogenic Agents is proposed in the upcoming project period, provide:

- A list of the new and/or additional Agent(s) that will be studied;
- A description of the work that will be done with the Agent(s), and whether or not the work is a restricted experiment;
- The title and location for each biocontainment resource/facility, including the name of the organization that operates the facility, and the biocontainment level at which the work will be conducted, with documentation of approval by the IBC or equivalent body or official. It is important to note if the work is being done in a new location;
- Any biosafety incidents that occurred and were reported to NIH/NIAID.

SPREADSHEET SUMMARY**AWARD NUMBER:** 5R01AI110964-07**INSTITUTION:** EcoHealth Alliance

Budget	Year 7	Year 8	Year 9	Year 10
Salaries and Wages	\$151,359	\$151,359	\$151,359	\$151,359
Fringe Benefits	\$47,686	\$47,686	\$47,686	\$47,686
Personnel Costs (Subtotal)	\$199,045	\$199,045	\$199,045	\$199,045
Consultant Services	\$38,337	\$38,337	\$38,337	\$38,337
Travel	\$30,417	\$30,417	\$30,417	\$30,417
Other	\$19,276	\$13,276	\$13,276	\$13,276
Subawards/Consortium/Contractual Costs	\$189,431	\$189,431	\$189,431	\$189,431
Publication Costs	\$6,000	\$6,000	\$6,000	\$6,000
TOTAL FEDERAL DC	\$482,506	\$476,506	\$476,506	\$476,506
TOTAL FEDERAL F&A	\$93,784	\$91,864	\$91,864	\$91,864
TOTAL COST	\$576,290	\$568,370	\$568,370	\$568,370

Facilities and Administrative Costs	Year 7	Year 8	Year 9	Year 10
F&A Cost Rate 1	32%	32%	32%	32%
F&A Cost Base 1	\$293,075	\$287,075	\$287,075	\$287,075
F&A Costs 1	\$93,784	\$91,864	\$91,864	\$91,864